Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients

Autor:	Xueding Wang, Chuncao Xu, Min Huang, Liemin Zhou, Hongliang Li, Yibei Chen, Dingsheng Wen, Xupeng Bai, Jing Jin
Rok vydání:	2018
Předmět:	Adult CD36 Antigens Male 0301 basic medicine medicine.medical_specialty Adolescent Peroxisome proliferator-activated receptor Single-nucleotide polymorphism Weight Gain Polymorphism Single Nucleotide Body Mass Index Young Adult 03 medical and health sciences Epilepsy 0302 clinical medicine Asian People Internal medicine Genotype medicine Humans Obesity Allele Alleles Pharmacology chemistry.chemical_classification business.industry Valproic Acid Body Weight medicine.disease PPAR gamma 030104 developmental biology Endocrinology chemistry Anticonvulsants Female lipids (amino acids peptides and proteins) medicine.symptom business Weight gain Body mass index 030217 neurology & neurosurgery
Zdroj:	Psychopharmacology. 235:2665-2673
ISSN:	1432-2072 0033-3158
DOI:	10.1007/s00213-018-4960-2
Popis:	Valproate (VPA) is a choice for the treatment of primary generalized epilepsies and partial epilepsies. Unfortunately, weight gain or obesity is one of the most frequent adverse effects of VPA treatment. Genetic factors were shown to be involved in the effect. The aim of this study was to investigate the association of selected single nucleotide polymorphisms (SNPs) of cluster of differentiation 36 (CD36) and peroxisome proliferator-activated receptor γ (PPARγ) with VPA-induced weight gain and obesity in epileptic patients. A total of 225 Chinese Han epilepsy patients receiving VPA treatment were recruited in the study. Height and weight for the calculation of body mass index (BMI) were measured at the initiation of VPA therapy and in the follow-up examination. A BMI of 25 kg/m2 or higher was defined as obesity on the basis of the World Health Organization (WHO) criteria for Asian populations. Four SNPs in CD36 (rs1194197, rs7807607) and PPARγ (rs10865710, rs2920502) were genotyped using the Sequenom® MassArray iPlex platform. About 19.6% of epileptic patients receiving VPA therapy were found to become obese. After covariate analysis of age, gender, sex, height, initial BMI, and VPA dosage, the CD36 rs1194197 C allele and rs7807607 T allele (OR, 0.31; 95%CI, 0.13–0.72; P = 0.009 and OR, 0.38; 95%CI; 0.18–0.83; P = 0.02, respectively) were identified as protective factors for VPA-induced obesity. The PPARγ rs10865710 C allele carriers were found to be less likely to suffer from VPA-induced obesity compared with GG genotype carriers (OR, 0.04; 95%CI, 0.01–0.12; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e206193a2e3fb79949b8d733da6c361 https://doi.org/10.1007/s00213-018-4960-2 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.